{
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "document": {
    "pdf_name": "Liu_et_al.__2024_"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "a recombinant influenza vaccine (Flublok Quad rival ent by SanofiPasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d",
      "relevance_explanation": "This quote identifies Flublok (RIV4) as a recombinant influenza vaccine, supporting the claim that it is produced using a recombinant platform.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "These serum samples were tested by ELISA to evaluate the total binding antibodies against 8 recombinant HA proteins (rHA from both egg and cell propagated viruses of each of the 4 vaccine antigens), and 2 rHA stalk proteins (A (H1 N1) pdm09 HA stalk, and A (H3 N2) HA stalk).",
      "relevance_explanation": "This quote shows that recombinant HA proteins are central to the analysis of the Flublok vaccine, supporting the claim that recombinant HA is used in its production.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}